← All indications
Smoldering Multiple Myeloma
An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.
Drugs by status
Approved for this indication (1)
Phase 3 trials (5)
Phase 2 trials (28)
- IPH2101
- simvastatin
- sodium fluoride (18F)
- metformin
- denosumab
- urea
- bhq-880
- bi-505
- carfilzomib
- selinexor
- elotuzumab
- icosapent ethyl
- nivolumab
- ixazomib
- pd-l1 peptide vaccine
- allogeneic hematopoietic stem cells
- celecoxib
- cyclophosphamide
- enk cell
- fludarabine
- sargramostim
- Fluciclovine
- fludeoxyglucose f-18
- dexamethasone
- ciltacabtagene autoleucel
- Elranatamab
- teclistamab
- tg01 vaccine
Phase 1 trials (3)
Other trials (2)
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (37)
- AbbVie
- Takeda
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Pharmacyclics
- Novartis
- BioInvent International AB
- Innate Pharma
- PETHEMA Foundation
- National Institutes of Health (NIH)
- Harvard University
- Hoosier Cancer Research Network
- Marshall University
- New York University
- University of Rochester
- Wayne State University
- Mayo Clinic
- Tel Aviv University
- University of Colorado, Denver
- University of Copenhagen
- University of Utah
- Icahn School of Medicine at Mount Sinai
- City of Hope National Medical Center
- Janssen Pharmaceutica NV
- University of Texas at Houston
- Erasmus University Rotterdam
- University of Iceland
- Multiple Myeloma Research Consortium
- +7 more
Organization Involved with Phase 1 Indications (7)